Novartis shares tumbled more than 10% on September 8, 2026, wiping $30 billion off market value after a drug from its $12 billion Avidity acquisition failed a trial. Artisan Partners, among top 20 shareholders, publicly demanded board changes and improved dealmaking, citing value destruction including the MorphoSys acquisition written down months after the 2024 deal.
Nov 14, 2026 · 5 sources
Nov 13, 2026 · 2 sources
Nov 12, 2026 · 2 sources
Nov 11, 2026 · 7 sources
Story comments
Loading comments…